Projects per year
Abstract
We described bacterial killing and resistance emergence at various fixed concentrations of meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Time-kill studies were conducted utilizing nine isolates and a large range of concentrations. Within each strain and antibiotic, initial killing was similar, with concentrations ≥2×MIC. At many (strain-specific) concentrations causing substantial initial killing, regrowth occurred at 24-48h. For remaining concentrations, growth typically remained suppressed (<5-log10 cfu/mL). The concentrations of meropenem required to suppress regrowth ranged from 2–8×MIC for P. aeruginosa and 2–64×MIC for E. coli. For piperacillin/tazobactam, the equivalent concentrations ranged from 8–16×MIC for P. aeruginosa and 4–16×MIC for E. coli. The number of less-susceptible bacteria increased with rising concentrations before decreasing at even higher concentrations. Suppression of regrowth and resistance was substantially improved with higher concentrations (typically ≥8×MIC), suggesting a benefit of higher β-lactam concentrations beyond those required for maximum initial killing.
Original language | English |
---|---|
Pages (from-to) | 69-76 |
Number of pages | 8 |
Journal | Diagnostic Microbiology and Infectious Disease |
Volume | 91 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 May 2018 |
Keywords
- Bacterial killing
- beta-Lactam antibiotics
- In vitro studies
- Resistance
Projects
- 4 Finished
-
Centre for REdefining antibiotic use to reDUce resistanCE and prolong the lives of antibiotics (REDUCE)
Roberts, J. A. (Primary Chief Investigator (PCI)), Lipman, J. (Chief Investigator (CI)), Peake, S. (Chief Investigator (CI)), Turnidge, J. D. (Chief Investigator (CI)), Slavin, M. A. (Chief Investigator (CI)), Hopkins, P. M. A. (Chief Investigator (CI)), Landersdorfer, C. (Chief Investigator (CI)), Paul, S. K. (Chief Investigator (CI)), De Waele, J. (Chief Investigator (CI)), Joynt, G. (Chief Investigator (CI)) & Udy, A. (Associate Investigator (AI))
1/12/15 → 30/11/20
Project: Research
-
Combating bacterial 'superbugs' by innovative antibiotic combination strategies
Landersdorfer, C. (Primary Chief Investigator (PCI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/14 → 31/12/17
Project: Research
-
Dosing to maximise bacterial killing and prevent resistance in ICU
Kirkpatrick, C. (Primary Chief Investigator (PCI)), Bergen, P. (Chief Investigator (CI)), Landersdorfer, C. (Chief Investigator (CI)) & Wirth, H.-J. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/14 → 31/12/16
Project: Research